Research programme: angiogenesis inhibitors - PTC Therapeutics

Drug Profile

Research programme: angiogenesis inhibitors - PTC Therapeutics

Alternative Names: VEGF inhibitors - PTC Therapeutics

Latest Information Update: 27 Jul 2010

Price : $50

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Jul 2010 Preclinical development is ongoing in USA
  • 28 Aug 2007 Lead identification is ongoing
  • 10 May 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top